Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

1987 • 2,769 citations

Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer

1987 • 1,224 citations

Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors

1984 • 845 citations

High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

1987 • 797 citations

High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer

1986 • 459 citations

Autologous Bone Marrow Transplantation in Patients with Acute Nonlymphocytic Leukemia, Using ex Vivo Marrow Treatment with 4-Hydroperoxycyclophosphamide

1986 • 454 citations

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

1985 • 293 citations

Prolonged Disease-Free Survival after Autologous Bone Marrow Transplantation in Patients with Non-Hodgkin's Lymphoma with a Poor Prognosis

1987 • 273 citations

High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma

1987 • 270 citations

Induction of NK cell activity against fresh human leukemia in culture with interleukin 2.

1987 • 215 citations

Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells

1986 • 179 citations

Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle.

1990 • 174 citations

Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients

1987 • 166 citations

Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission

1989 • 162 citations

Immunologic reconstitution after human marrow grafting.

1984 • 154 citations

An Acquired Chemotactic Defect in Neutrophils from Patients Receiving Interleukin-2 Immunotherapy

1990 • 149 citations

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.

1988 • 138 citations

Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation

1990 • 112 citations

Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy

1989 • 93 citations

A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease

1989 • 89 citations

High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease

1986 • 72 citations

Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.

1989 • 72 citations

Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow

1987 • 52 citations

Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents

1989 • 38 citations

Receptor-specific inhibition of bone marrow erythropoiesis by recombinant DNA-derived interleukin-2

1987 • 24 citations

Receptor-specific modulation of myelopoiesis by recombinant DNA-derived interleukin 2.

1987 • 20 citations